Exubera in 2006?
This article was originally published in RPM Report
Executive Summary
Pfizer and Sanofi-Aventis will have to wait a little longer to launch inhaled insulin (Exubera). FDA is taking a three month extension to the review, meaning a decision should come before the end of January.
You may also be interested in...
Inhaled Insulin: Being First Isn't Necessarily Best
The early bird may get the worm, but it's the second mouse that finds the cheese. This has proven true many times in the drug industry in the past. It may prove true once again with inhaled insulin.
Inhaled Insulin: Being First Isn't Necessarily Best
The early bird may get the worm, but it's the second mouse that finds the cheese. This has proven true many times in the drug industry in the past. It may prove true once again with inhaled insulin.
Pfizer's Exubera: Breathing New Life Into Inhaled Insulin
Dragging a host of safety concerns, Exubera hardly inspired confidence when it went before an FDA advisory committee. But Pfizer proposed an aggressive risk management scheme that won it a dramatic "yes" vote. How one company addressed a drug's safety concerns head-on to win the confidence of FDA's advisors.